In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Caris Life Sciences Inc (NASDAQ: CAI) was $30.33 for the day, up 0.26% from the previous closing price of $30.25. In other words, the price has increased by $0.26 from its previous closing price. On the day, 0.76 million shares were traded. CAI stock price reached its highest trading level at $31.34 during the session, while it also had its lowest trading level at $30.14.
Ratios:
Our analysis of CAI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.79 and its Current Ratio is at 9.24. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wolfe Research on July 14, 2025, initiated with a Outperform rating and assigned the stock a target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.
On July 14, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $31.JP Morgan initiated its Overweight rating on July 14, 2025, with a $31 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 20 ’25 when Denton John Russel bought 7,500 shares for $21.00 per share. The transaction valued at 157,500 led to the insider holds 123,591 shares of the business.
Brille Brian J bought 30,000 shares of CAI for $630,000 on Jun 20 ’25. The insider now owns 162,428 shares after completing the transaction at $21.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 8530850816 and an Enterprise Value of 8227324928. Its current Enterprise Value per Revenue stands at 15.411 whereas that against EBITDA is -58.443.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $42.50, while it has fallen to a 52-week low of $25.40. The 50-Day Moving Average of the stock is -8.10%, while the 200-Day Moving Average is calculated to be -3.18%.
Shares Statistics:
CAI traded an average of 656.38K shares per day over the past three months and 971120 shares per day over the past ten days. A total of 281.09M shares are outstanding, with a floating share count of 114.95M. Insiders hold about 59.13% of the company’s shares, while institutions hold 35.91% stake in the company. Shares short for CAI as of 1757894400 were 1900431 with a Short Ratio of 2.90, compared to 1755216000 on 1733651. Therefore, it implies a Short% of Shares Outstanding of 1900431 and a Short% of Float of 1.3099999.
Earnings Estimates
At present, 6 analysts are actively evaluating the performance of Caris Life Sciences Inc (CAI) in the stock market.The consensus estimate for the next quarter is $0.02, with high estimates of $0.08 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.85 and -$8.86 for the fiscal current year, implying an average EPS of -$2.52. EPS for the following year is $0.26, with 6.0 analysts recommending between $0.49 and -$0.05.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $205.37M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.01M.
Based on 8 analysts’ estimates, the company’s revenue will be $977.6M in the next fiscal year. The high estimate is $1.01B and the low estimate is $955.4M.
